Abstract: Disclosed is a specimen measurement apparatus comprising: a measurement unit configured to suction a specimen from a specimen container and measure the suctioned specimen; and a specimen transport unit configured to transport the specimen container to the measurement unit, wherein the specimen transport unit includes a rack setting part configured to allow a specimen rack to be set thereon, the specimen rack holding the specimen container that has not been subjected to specimen suction by the measurement unit, a rack collection part configured to collect the specimen rack holding the specimen container that has been subjected to specimen suction by the measurement unit, and an interruption specimen setting part configured to allow the specimen rack to be set thereon, the specimen rack holding the specimen container that is to be subjected to specimen suction by the measurement unit in preference to the specimen container held by the specimen rack having been set on the rack setting part, and the interruption

Abstract: The present invention provides an antipsychotic drug comprising fasudil or a pharmaceutically acceptable salt thereof as an active agent for the treatment of schizophrenia, including schizophrenia caused by dysfunction of ARHGAP10.

Abstract: An object of the present invention is to provide a novel therapeutic agent for a mental disorder with abnormal neurodevelopment as a pathological condition. The present invention provides an antipsychotic drug containing a Rho kinase inhibitor as an active ingredient. The antipsychotic drug can be used, for example, in the treatment of schizophrenia, autism spectrum disorder, bipolar disorder, or depression.

Abstract: An object of the present invention is to provide a novel therapeutic agent for a mental disorder with abnormal neurodevelopment as a pathological condition. The present invention provides an antipsychotic drug containing a Rho kinase inhibitor as an active ingredient. The antipsychotic drug can be used, for example, in the treatment of schizophrenia, autism spectrum disorder, bipolar disorder, or depression.

Abstract: The object of the present invention is to provide an antibody capable of immunologically and specifically binding to a folate receptor ? and a folate receptor ?. Specifically, the present invention relates to an antibody or a fragment thereof, in which the amino acid sequences of CDRH1, CDRH2, and CDRH3 of a heavy chain variable region (VH) are SEQ ID NOs: 2, 4, and 6, respectively, and the amino acid sequences of CDRL1, CDRL2, and CDRL3 of a light chain variable region (VL) are SEQ ID NOs: 10, 12, and 14, respectively.

Abstract: The object of the present invention is to provide an antibody capable of immunologically and specifically binding to a folate receptor ? and a folate receptor ?. Specifically, the present invention relates to an antibody or a fragment thereof, in which the amino acid sequences of CDRH1, CDRH2, and CDRH3 of a heavy chain variable region (VH) are SEQ ID NOs: 2, 4, and 6, respectively, and the amino acid sequences of CDRL1, CDRL2, and CDRL3 of a light chain variable region (VL) are SEQ ID NOs: 10, 12, and 14, respectively.

Abstract: The object is to provide a combination of biomarkers which allow highly accurate discrimination of schizophrenia, and a utilization thereof. A combination of schizophrenia marker set including a combination of two or more protein molecules selected from the group consisting of trifunctional purine biosynthetic protein adenosine-3, uroporphyrinogen decarboxylase, interferon-induced GTP-binding protein Mx1, glutaredoxin-3, microtubule-associated protein RP/EB family member 1, tubulin folding cofactor B, immunoglobulin mu chain C region, and heat shock 70 kDa protein 4L is provided. In addition, a method for examining schizophrenia using the level of the marker set in a specimen as an index is provided.

Abstract: An object of the present invention is to provide a cartilage/bone destruction suppressor which can suppress the destruction of cartilage or bone seen in rheumatoid arthritis, osteoarthritis, bone metastasis of malignant tumor, or the like. The present invention relates to a cartilage or bone destruction suppressor comprising an antibody against folate receptor ? or a complex of the antibody and a biologically or chemically active substance.

Abstract: It is intended to ameliorate arteriosclerosis or arteriosclerotic disease through a pharmacological mechanism that reduces the size of the arteriosclerotic lesion. The agent of the present invention comprises a complex comprising an antibody binding to folate receptor ? (FR?) and a cytotoxin or a cytotoxic agent conjugated with the antibody, or the antibody as an active ingredient.

Abstract: An objective of the present invention is to provide a therapeutic agent for treating rheumatoid arthritis, juvenile rheumatoid arthritis, macrophage activation syndrome, septicemia, and FR-? expressing leukemia, which induces apoptosis in activated macrophages and folate receptor beta (FR-?) expressing leukemia cells to specifically destroy these cells. An FR-? monoclonal antibody of the present invention is preferably an IgG-type monoclonal antibody which specifically reacts with a human-type FR-? antigen and is produced from a clone resulting from immunization with an FR-? expressing B300-19 cell. The FR-? monoclonal antibody of the present invention specifically reacts with the FR-? antigen of activated macrophages and FR-? expressing leukemia cells and a therapeutic agent of the present invention contains an FR-? antibody immunotoxin which causes apoptosis in activated macrophages and FR-? expressing leukemia cells, as an active ingredient.

Abstract: A process of fabricating a semiconductor integrated circuit device, wherein a semiconductor wafer having a number of isolated active areas has a gate insulator layer located within each active area and defining regions to form source and drain regions, respectively, and a gate electrode layer formed on the gate insulator layer, and wherein dopant ions are injected into the source- and drain-forming regions in two steps consisting of a first step of injecting dopant ions in a first direction inclined through a predetermined angle from normal to the surface of the wafer, the first direction having on a plane parallel with the surface of the wafer a projective component angled to the direction of length of the gate electrode layer, the dopant ions being injected into the source- and drain-forming regions with a dose equal to one-half of the total dose required for the formation of the source and drain regions, and a second step of injecting dopant ions in a second direction inclined through the predetermined ang